SINOFUTURE PHARMA

Sinofuture Pharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to developing next-generation treatments for metabolic and chronic diseases. The company's primary focus is on the development of multi-target agonists, with its lead program, SF-001, currently in Phase 2 clinical trials for metabolic-associated steatohepatitis (MASH) and type 2 diabetes. Sinofuture utilizes a proprietary technology platform to optimize the pharmacological profiles of peptide and small molecule candidates. By targeting complex metabolic pathways, the company aims to provide more effective therapeutic options for patients with obesity and related comorbidities. Sinofuture is backed by prominent venture capital firms and continues to expand its pipeline into oncology and other high-value therapeutic areas.